Calmare Therapeutics Inc (fka CTTC)

[andy55q]

Int J STD AIDS. 2017 Feb;28(2):202-204. doi: 10.1177/0956462416656688. Epub 2016 Jul 10.
Treatment of human immunodeficiency virus-related peripheral neuropathy with Scrambler Therapy: a case report.
Smith TJ1, Auwaerter P2, Knowlton A3, Saylor D4, McArthur J4.
Author information

11 From the Harry J. Duffey Family Palliative Care Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
22 Division of Infectious Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA.
33 Department of Health Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
44 Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract
Peripheral neuropathy is one of the most common neurological complications of HIV infection with a 30-60% lifetime prevalence. Newer HIV drugs cause less peripheral neuropathy, but patients are now living long enough to develop concomitant diabetes-related, vascular-related, and chemotherapy-related neuropathy so it continues as a major debilitating issue. Recent national CDC guidelines have stressed the importance of non-opioid therapies, especially in this population that may have had drug abuse problems. We treated a 52-year-old man who had severe disabling classic peripheral neuropathy since 1998 with Scrambler Therapy (Calmare), an FDA-cleared peripheral non-invasive neuromodulation device. His pain rapidly improved, as did his motor and sensory function, with just four 45-min treatments, and he was able to come off opioids for the first time in years. When his pain returned six months later, only two treatments were needed to resolve it. This represents the first published use of this novel, inexpensive, and non-invasive pain modality in HIV peripheral neuropathy, and should engender further trials.
KEYWORDS:
HIV-associated neuropathy; neuromodulation; neuropathic pain; scrambler therapy
https://www.ncbi.nlm.nih.gov/pubmed/27330020